[Control of bone remodeling by bone anabolic drugs.]
Teriparatide is a bone anabolic drug that is only available in practice. It is a N-terminal fragment of parathyroid hormone(PTH). Mode of actions of teriparatide is pharmacological but not physiological as it is administered to patients with osteoporosis. Physicians need to understand the fact that treatment with teriparatide is not just like a hormone replacement but its effects on bone remodeling are pharmacological. Romosozumab, under clinical development as anti-osteoporosis drug, is a monoclonal antibody against sclerostin. Clinical data demonstrate that it temporally, but robustly activates bone formation as well as inhibits bone resorption. Thus, romosozumab is expected to have a strong anabolic action on bone remodeling.